US EditionPublished • loading... • Updated
Glenmark Pharmaceuticals receives EIR from US FDA for its Monroe facility
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Glenmark Pharmaceuticals receives EIR from US FDA for its Monroe facility
Glenmark Pharmaceuticals, a research-led, global pharmaceutical company announced that it has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its formulations manufacturing facility in Monroe, North Carolina (USA) with a Voluntary Action Indicated (VAI) status. The inspection was conducted at the Company’s manufacturing facility from 09 June to 17 June 2025. The post Glenmark Pharmaceuti…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
